Worldwide Peripheral Neuropathy Emerging Market & Product Assessment

This new EP Publications report:

• Projects the number of patients with key conditions associated with peripheral neuropathy in 2007 and 2012
• Reveals vital differences between novel compounds in development to treat peripheral neuropathy
• Uncovers the factors and players that will drive the growth of the emerging peripheral neuropathy market
• Predicts the commercial potential for current and upcoming drug classes in individual country markets
• Forecasts the value (in USD) of the peripheral neuropathy market, by drug class, by condition, and by country, in 2007 and 2012

Currently, there are no treatments commercially available to effectively prevent, reduce, or reverse damage to peripheral nerves, or peripheral neuropathy. By 2012, there will be over 1.5 million individuals in the seven major pharmaceutical markets ? U.S., France, Germany, Italy, Spain, UK, and Japan who suffer from peripheral neuropathy caused from a wide array of factors, including certain major medical conditions (e.g., diabetes, HIV/AIDS) and chemical toxicity (e.g., chemotherapy treatment of cancer).

Peripheral neuropathy is currently managed primarily through controlling the cause of the damage ? for diabetes and HIV/AIDS patients, this represents treating the diseases, while for cancer patients, this means limiting doses of chemotherapy or tolerating significant pain or loss of sensation.

Effective prevention and treatment of peripheral neuropathy would:

• Improve quality of life for patients with diabetes or HIV/AIDS by providing relief from progressing levels of pain symptoms
• Facilitate full dosing of life-saving chemotherapeutics known to cause peripheral neuropathy

In this report, WWMR, Inc., provides an overview of peripheral neuropathy in the seven major pharmaeutical markets:

• U.S.
• France
• Germany
• Italy
• Spain
• UK
• Japan

Models representing patient populations and the commercial value (USD) of this emerging market through 2012 are presented in a series of tables, charts, and text commentary describing the important features of the key conditions associated with peripheral neuropathy:

• Diabetes
• HIV/AIDS
• Chemotherapy treatment

Models and commentary describing the current and future peripheral neuropathy market are based on:

• In-depth analysis of the medical literature, including treatment review articles, medical textbooks, epidemiological studies, and clinical trials
• Thorough review of country-specific and overall trends, as well as country-to-country comparisons, of prescriptions written for specific conditions
• Analysis of drugs in the peripheral neuropathy drug pipeline and the future directions in treatment
• Interviews with clinicians, including medical directors of selected pain centers and clinicians treating peripheral neuropathy

WWMR�fs Worldwide Peripheral Neuropathy report will allow pharmaceutical and biotechnology executives to:

• Recognize the specific conditions associated with peripheral neuropathy that have high market potential in the next 10 years
• Understand the type and level of unmet need in the peripheral neuropathy market in the US, France, Germany, Italy, Spain, UK, and Japan
• Compare the epidemiology of peripheral neuropathy among the 7 major pharmaceutical markets, including projected growth rates
• Target specific patient populations who will benefit most from drugs in the peripheral neuropathy pipeline
• Anticipate upcoming competitors and product licensing opportunities
• Recognize the impact of special market dynamics, including potential off-label usage, on product uptake forecasts
• Develop condition- and country-specific forecasts for major conditions associated with peripheral neuropathy